Related Experiment Videos
Is pre-treatment testosterone a prognostic factor in prostate cancer?
1University of Benin Teaching Hospital, Nigeria.
The Central African Journal of Medicine
|August 1, 1993
Summary
Pre-treatment testosterone levels significantly impact prostate cancer prognosis. Low testosterone levels correlate with a poor outlook after bilateral orchidectomy, showing 100% mortality within one year.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostate cancer treatment often involves hormonal manipulation.
- Testosterone's role in prostate cancer progression is a key area of research.
Purpose of the Study:
- To investigate the prognostic significance of pre-treatment testosterone levels in prostate cancer patients.
- To correlate testosterone levels with outcomes following bilateral orchidectomy.
Main Methods:
- Measurement of pre-treatment serum testosterone levels in prostate cancer patients.
- Analysis of patient outcomes, including mortality, after bilateral orchidectomy based on initial testosterone levels.
Main Results:
- Pre-treatment testosterone level was identified as a significant prognostic factor.
- Patients with very low testosterone levels experienced a 100% mortality rate within one year post-orchidectomy.
- Patients with normal testosterone levels had a 27% one-year mortality rate.
Conclusions:
- Pre-treatment testosterone levels are critical for predicting prognosis in prostate cancer.
- Bilateral orchidectomy outcomes are markedly worse in patients with pre-existing low testosterone levels.